Article Text

Download PDFPDF
Original article
Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink
  1. Zhiwei Liu1,
  2. Rotana Alsaggaf1,
  3. Katherine A McGlynn1,
  4. Lesley A Anderson2,
  5. Huei-Ting Tsai3,4,
  6. Bin Zhu1,
  7. Yue Zhu5,
  8. Sam M Mbulaiteye1,
  9. Shahinaz M Gadalla1,
  10. Jill Koshiol1
  1. 1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
  2. 2 Centre for Public Health, School of Medicine, Dentistry and Biomedical Science, Queen’s University Belfast, Belfast, UK
  3. 3 Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA
  4. 4 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Georgetown University, Washington, DC, USA
  5. 5 Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA
  1. Correspondence to Dr Zhiwei Liu, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20850, USA; zhiwei.liu{at}nih.gov

Footnotes

  • Contributors ZL was involved in the study design, analysis and interpretation of data and writing the manuscript. RA, KAM, LAA, HTT, YZ, SMM and SMG were involved in conception of the study, interpretation of data and revision of the manuscript. BZ was involved in data analysis, interpretation of data and revision of the manuscript. JK was involved in conception of the study, study design, interpretation of data and writing the manuscript. All authors revised the article critically for important intellectual content and gave final approval of the version to be published.

  • Funding Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.

  • Disclaimer The funders had no role in the conduct of this research. The views expressed in this article are those of the authors and not necessarily those of the US Food and Drug Administration.

  • Competing interests HTT is currently an employee of the US Food and Drug Administration.

  • Patient consent Not required.

  • Ethics approval Independent Scientific Advisory Committee of the CPRD (proposal number 17_160.R).

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors ZL was involved in the study design, analysis and interpretation of data and writing the manuscript. RA, KAM, LAA, HTT, YZ, SMM and SMG were involved in conception of the study, interpretation of data and revision of the manuscript. BZ was involved in data analysis, interpretation of data and revision of the manuscript. JK was involved in conception of the study, study design, interpretation of data and writing the manuscript. All authors revised the article critically for important intellectual content and gave final approval of the version to be published.

  • Funding Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.

  • Disclaimer The funders had no role in the conduct of this research. The views expressed in this article are those of the authors and not necessarily those of the US Food and Drug Administration.

  • Competing interests HTT is currently an employee of the US Food and Drug Administration.

  • Patient consent Not required.

  • Ethics approval Independent Scientific Advisory Committee of the CPRD (proposal number 17_160.R).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.